TORNTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.2
| Stock Code | TORNTPHARM | Market Cap | 1,36,454 Cr. | Current Price | 4,032 ₹ | High / Low | 4,125 ₹ |
| Stock P/E | 63.9 | Book Value | 250 ₹ | Dividend Yield | 0.80 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 3,888 ₹ | DMA 200 | 3,617 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.12 % | PAT Qtr | 606 Cr. | PAT Prev Qtr | 551 Cr. |
| RSI | 57.1 | MACD | 36.6 | Volume | 3,25,019 | Avg Vol 1Wk | 3,35,933 |
| Low price | 2,886 ₹ | High price | 4,125 ₹ | PEG Ratio | 2.63 | Debt to equity | 0.25 |
| 52w Index | 92.5 % | Qtr Profit Var | 31.8 % | EPS | 62.3 ₹ | Industry PE | 29.1 |
📊 Analysis: TORNTPHARM shows strong potential for intraday trading. Current price (₹4,032) is above both 50 DMA (₹3,888) and 200 DMA (₹3,617), reflecting bullish momentum. RSI at 57.1 is moderately strong but not overbought, while MACD (36.6) indicates positive momentum. Volume (3.25L vs avg 3.35L) is stable, supporting intraday participation. Valuation is expensive with P/E at 63.9 compared to industry PE of 29.1, but strong fundamentals and profit growth provide confidence.
💰 Optimal Buy Price: ₹4,020–4,035 if price sustains above support.
📈 Profit-Taking Levels: First exit near ₹4,070, extended target ₹4,110.
📉 Stop-Loss: ₹3,990 to protect against downside risk.
⏱️ If Already Holding: Exit intraday if price fails to hold above ₹4,020 or momentum weakens near resistance zones (₹4,070–4,110). Watch RSI crossing above 65–70 (overbought) or volume tapering off as exit signals.
Positive
- EPS at ₹62.3 reflects strong profitability.
- ROCE (27.8%) and ROE (26.2%) highlight operational efficiency.
- Price trading above both 50 DMA and 200 DMA signals bullish trend.
- Quarterly PAT improved (₹606 Cr vs ₹551 Cr), showing earnings growth.
Limitation
- High P/E (63.9) compared to industry average (29.1), indicating premium valuation.
- PEG ratio (2.63) suggests expensive valuation relative to growth.
- DII holdings decreased (-0.12%), showing reduced domestic institutional support.
Company Negative News
- Valuation concerns due to high P/E and PEG ratio.
- Minor decline in DII holdings indicates cautious sentiment.
Company Positive News
- Quarterly profit growth of 31.8% highlights strong performance.
- FII holdings increased (+0.21%), reflecting foreign investor confidence.
- Stock trading near 52-week high (₹4,125) shows strong investor sentiment.
Industry
- Industry PE at 29.1 indicates sector is moderately valued compared to TORNTPHARM’s premium.
- Pharmaceutical sector remains resilient with consistent demand outlook.
Conclusion
⚖️ TORNTPHARM is a strong candidate for intraday trading. Entry near ₹4,020–4,035 with exit around ₹4,070–4,110 offers a favorable risk-reward setup. Traders should remain cautious due to high valuation, but bullish technicals and strong fundamentals provide momentum-driven upside.